Multiple genetic alterations occur in melanoma, a lethal skin malignancy of increasing incidence 1,2 . These include mutations that activate Ras and two of its effector cascades, Raf and phosphoinositide 3-kinase (PI3K). Induction of Ras and Raf can be caused by active N-Ras and B-Raf mutants as well as by gene amplification [3] [4] [5] . Activation of PI3K pathway components occurs by PTEN loss and by AKT3 amplification [6] [7] [8] . Melanomas also commonly show impairment of the p16 INK4A -CDK4-Rb and ARF-HDM2-p53 tumor suppressor pathways. CDKN2A mutations can produce p16 INK4A and ARF protein loss 5,9-11 . Rb bypass can also occur through activating CDK4 mutations as well as by CDK4 amplification 5, 12 . In addition to ARF deletion, p53 pathway disruption can result from dominant negative TP53 mutations 5, 13 . TERT amplification also occurs in melanoma 5 . The extent to which these mutations can induce human melanocytic neoplasia is unknown. Here we characterize pathways sufficient to generate human melanocytic neoplasia and show that genetically altered human tissue facilitates functional analysis of mutations observed in human tumors.
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Determining whether mutations identified in specimens from melanomas and other human cancers have true oncogenic potential or instead represent secondary associations has been difficult. Murine models may not entirely reflect human oncogene action 14 , as shown by species differences in pathways engaged by oncogenic Ras 15 . Moreover, murine tissue architecture can differ markedly from that of humans. For example, murine melanocytes reside in the hair follicle 16 , whereas most human melanocytes and melanomas are located outside hair structures. Studies in mice suggest that oncogenic Ras in the context of p16 INK4A and ARF loss increases melanoma frequency 17, 18 . But oncogene activation during development can produce very different effects from activation in the adult 19 , tempering extrapolation of these findings to the somatic cell carcinogenesis that occurs in adult humans. Moreover, melanomas observed in murine models arise stochastically in only a subset of animals, indicating that additional uncharacterized changes are involved. Models testing oncogenic sufficiency would therefore benefit from the introduction of defined genetic alterations in a developmentally mature human tissue context. This may be possible in skin, which can be regenerated from primary human cells on immunodeficient mice to accurately recapitulate the threedimensional architecture, matrix elements and gene expression patterns of adult human tissue 20, 21 .
To characterize the functional impact of genetic alterations associated with human melanoma, we generated human skin tissue containing melanocytes selectively engineered to express specific mutations found in human melanoma. Because melanoma is embedded in stratified epithelial tissue, we combined freshly isolated primary human keratinocytes with melanocytes on human dermis and regenerated human skin in vivo on immunodeficient mice (Fig. 1a) . First, we introduced multiple genes into melanocytes using rapid serial retroviral transductions 21 . Mutants found in human melanoma, which produce activated Ras (N-Ras G12V ), as well as disruptions of the Rb (active CDK4 R24C ) and p53 pathways (dominant negative p53 R248W ; p53 DN ), were expressed in human melanocytes (Fig. 1b) along with the wild-type catalytic subunit of human telomerase (hTERT). None of these mutants, singly or in combination, substantially altered proliferation or cell viability (Supplementary Fig. 1 online and data not shown). Expression of Ras mutants increased active ERK MAP kinases to levels similar to those seen in SK-Mel-2 melanoma cells that contain an activating mutation in an endogenous NRAS allele, confirming that Ras pathway action was comparable to that occurring in at least some human melanoma cells (Fig. 1c) . p53 DN function was confirmed using p53 reporter activity (Fig. 1d) . Activity of delivered hTERT was confirmed by TRAP assay (Fig. 1e) . These data confirm that functionally active genetic elements found in human melanoma were introduced into primary human melanocytes.
We analyzed human skin tissue regenerated with melanocytes expressing combinations of the genes noted starting 4 weeks after grafting (n Z 5 mice per gene combination; data not shown). Rb and p53 pathway inhibition in concert with hTERT produced no effects, but addition of active Ras to this combination produced clinical and histologic features of invasive human melanoma. Clinically, this manifested as darkly pigmented skin that progressed to ulcerated tumor nodules (Fig. 2a) . Histologic features were characteristic of melanoma, including asymmetric junctional melanocytic hyperplasia, pagetoid spread upwards into the epidermis, deep vertical invasion into the dermis and tumor vascularization ( (Fig. 2c) . Melanocytic neoplasms showed the wide range of characteristics seen in human melanoma, including variation in cell morphology and degree of pigmentation. As in spontaneous human melanomas, invasive tumor cells had S100 and Melan-A melanocyte markers as well as the HMB45 melanoma marker but lacked epithelial keratins (Fig. 2d) . Therefore, genetically induced human melanocytic neoplasia has the cardinal clinical, histologic and immunophenotypic features of invasive melanoma. Tumor cells expressed all the genes that we introduced ( Fig. 2e and Supplementary Fig. 3 online) . Five independent attempts to reisolate and grow melanocytes from tumors in adequate numbers for analysis failed, but Giemsa banding karyotypic analysis of cells expressing oncogenic combinations grown in parallel in vitro for 8 months showed no evidence of genetic instability that might introduce additional genetic changes. Detection of heterogeneous marker genes in cutaneous tumors generated from melanocytes marked at low efficiency indicated that tumors were polyclonal ( Supplementary  Fig. 4 online) . Despite aggressive local invasion, no spontaneous visceral metastases were observed. Although it also produced locally invasive tumors, the A375 human melanoma cell line, which forms pulmonary tumors when injected intravenously into nude mice 22 , also failed to metastasize when incorporated with keratinocytes into regenerated human skin grafts ( Supplementary Fig. 5 online) . Human dermal and epithelial elements may therefore form a barrier to metastasis, the basis for which requires further study.
CDKN2A deletions in melanoma may alter the function of both p16 INK4A and ARF simultaneously, with resultant inhibition of Rb and p53 pathways. We next determined whether interfering with either pathway alone was sufficient to trigger human melanocytic neoplasia. Coexpression of either CDK4 or p53 DN with oncogenic Ras and hTERT induced invasive melanocytic neoplasia in human tissue (Fig. 3a) , indicating that disruption of either Rb or p53 pathway function alone could cooperate with Ras and hTERT in this process. Rb hyperphosphorylation occurred in melanocytes when Ras was coexpressed with either CDK4 or p53 DN ( Supplementary Fig. 6 online), suggesting that bypass of the Rb block occurs by both gene sets. We next examined the role of elevated telomerase activity in triggering neoplasia. hTERT supported progressively invasive melanocytic neoplasia, whereas only junctional melanocytic hyperplasia with minimal invasion developed without hTERT (Fig. 3b) . Melanocytes in tissue that did not receive hTERT maintained mitotic activity over the course of 6 months in vivo ( Supplementary Fig. 7 online) , suggesting that hTERT action in this context was not merely due to prevention of replicative exhaustion. PI3K and Raf initiate major effector pathways that are implicated independently of Ras in human melanoma. Although genetic and biochemical evidence supports the idea that both pathways are induced in a substantial proportion of human melanomas, their relative functional effects on tumorigenesis are unknown. Coexpression of active PI3K p110a with CDK4, p53 DN and hTERT produced invasive melanocytic neoplasia indistinguishable from that observed with oncogenic Ras (Fig. 4a,c) . In contrast, B-Raf V599E , the active mutant most frequently found in melanoma, induced only very mild junctional melanocytic nesting in this context, despite achieving comparable ERK1/2 activation to oncogenic Ras (Fig. 4b,c) . Levels of effector activation by both PI3K and B-Raf were comparable to those observed in genetically characterized melanoma cell lines with PTEN loss and endogenous mutant B-Raf V599E expression, respectively (Fig. 4a,b) , confirming signaling induction at magnitudes that occur in at least some melanoma cells. Coexpression of active B-Raf with PI3K p110a did not accelerate or increase the severity of melanocytic neoplasia over the course of 12 weeks. These data indicate that activation of PI3K, but not Raf, can replace Ras to induce invasive human melanocytic neoplasia.
Both active Ras and PI3K along with Rb and p53 inhibition as well as hTERT expression are sufficient to induce invasive human melanocytic neoplasia. B-Raf, though currently of intense interest in melanoma, lacked the oncogenic potency of either Ras or PI3K in the human skin tissue context that we studied. Because mutants are introduced nearly simultaneously, however, the present strategy does not exclude other potential outcomes that might occur with different sequences or timing of mutational events. Notably, BRAF mutations may occur at a higher frequency in benign nevi than in melanoma, whereas the opposite has been reported for NRAS 4 , underscoring the importance of future studies of the functional effects of B-Raf. In contrast, evidence for PI3K pathway induction occurs more frequently in melanoma than in benign nevi 7, 8 , consistent with our findings that activating PI3K pathway elements may be a more potent oncogenic stimulus.
The observation that interference with either Rb or p53 pathway function is oncogenic in the context of coexpression of Ras and hTERT is consistent with observations of human melanomas carrying CDKN2A mutations that selectively ablate the transcript encoding either p16 INK4A or ARF, as well as with murine data indicating that Ras can increase melanoma frequency in concert with deficiency of either protein 18, 23, 24 . Although we observed no short-term growth differences among gene-combination groups in vitro, both Rb and p53 pathways inhibit uncontrolled progression through the G1 phase of the cell cycle. Thus, long-term inhibition of the function of either protein in vivo may facilitate tumor growth through diminished G1 restraints. p53, however, has a variety of tumor-suppressive effects, and understanding its precise role in this context requires further study. hTERT coexpression, though dispensable for early stages of melanocytic hyperplasia, was required to induce progressively invasive melanocytic neoplasia. Cessation of mitotic activity in the absence of hTERT coexpression did not accompany this finding, consistent with its reported effects on tumorigenesis beyond promoting immortalization 25, 26 . These data assess the oncogenic capacity of specific genetic alterations observed in human melanoma and identify a minimal set of genetic changes sufficient to induce this neoplasm in human skin tissue. Use of genetically engineered human tissue may thus provide a general means of testing the oncogenic potency of genetic alterations identified in other human tumors and of developing models for assessment of new therapeutics aimed at such genetic targets.
METHODS
Cell growth. We isolated normal human keratinocytes and normal human melanocytes from human skin, including adult abdominal and breast skin as well as neonatal foreskin, from approximately ten unrelated individuals. Cells from all tissues used produced similar results, with no donor-linked differences observed. We grew keratinocytes in steroid-free medium (GIBCO/BRL) and melanocytes in medium154 (Cascade Biologics) containing phorbol ester; the latter was necessary for cell growth in vitro but not sufficient for subsequent tumorigenesis. We purchased melanoma cell lines A375, SK-Mel-24, SK-Mel-31, WM115 and SK-Mel-2 from ATCC. We grew cells in Dulbecco's modified Eagle medium (GIBCO/BRL) supplemented with 10% (for A375, SK-Mel-2, SK-Mel-24 and WM115 cells) or 15% (for SK-Mel-31 cells) fetal bovine serum (Omega Scientific). Giemsa banding was carried out at the Stanford Cytogenetics Laboratory.
Gene transfer. We used the pLZRS retroviral backbone 27 to express all the genes studied and verified sequences by sequencing both vector strands. We purchased the human N-Ras G12V coding sequence from the Guthrie cDNA Resource Center and subcloned it into the BamHI-XhoI sites of pLZRS. We subcloned the coding sequence of active PI3K p110a-CAAX into the BamHI site of pLZRS (courtesy of T. Cai; Stanford University, Stanford, California, USA). We subcloned human Myc-tagged B-Raf V599E cDNA (a gift from R. Marais; The Institute of Cancer Research, London, UK) into the XmnIXbaI sites of pENTR1A (Invitrogen) to make pENTR1A-B-Raf. To remove the 3¢ untranslated region, we used pENTR1A-B-Raf as a PCR template (primer sequences are available on request). We digested the resulting product with BglII and XbaI and used it to replace the original BglII-XbaI fragment of pENTR1A-B-Raf to make pENTR1A-B-Raf-noUTR. We then transferred the B-Raf V599E coding sequence into pLZRS containing a GATEWAY (Invitrogen) destination site (pLZRS-GATEWAY). Vectors for H-Ras G12V , CDK4 R24C , p53 R248W and hTERT have been described previously 21 . We made plates coated with extracellular matrix by lysing confluent keratinocytes in 34 mM ammonium hydroxide and rinsing away cell debris with phosphate-buffered saline (GIBCO/BRL). We seeded melanocytes on plates coated with extracellular matrix and transduced them by multiplex serial gene transfer at multiplicities of infection of 10 to 15 with retroviral vectors using low-speed centrifugation at intervals of 12-24 h (refs. 21,28) . We used no drug selection in any experiment.
Animal studies. At 48-72 h after multiplex serial gene transfer, we combined transduced melanocytes with nontransduced keratinocytes on devitalized human dermal substrate at a ratio of 1:5 (melanocyte:keratinocyte), which has been proposed as the physiological ratio of epidermal melanocytes to basal keratinocytes 29 . Seven days after seeding, we grafted tissue onto CB.17 scid/scid mice as described 21 . Before seeding, we confirmed expression of the introduced genes in melanocytes by immunoblotting as noted below. All studies were done with multiple replicates in separate rounds of experiments (n ¼ 5-25 mice per group). We tested N-Ras G12V and H-Ras G12V in parallel; they produced melanocytic neoplasms with identical features. For B-Raf studies, we carried out 25 independent grafts in five rounds of experiments to confirm the observed results. We analyzed human skin tissue initially at 4-12 weeks with matched tissue from all the different experimental groups collected at each time point. Findings in individual grafts were consistent for each gene set studied.
For hTERT progression studies, we collected skin tissue at approximately 4, 12 and 24 weeks after grafting. At the time of skin tissue collection, we killed the mice and examined visceral organs for metastases clinically and histologically. Tumor burden in skin was estimated to be 5-10 Â 10 7 melanocytic cells at 24 weeks, by cross-sectional cell counting of tissue sections and calculation of tumor volumes. We regenerated human skin tissue containing A375 melanoma cells and analyzed it as described above, with A375 cells used in place of genetically engineered melanocytes.
Gene and protein expression analysis. For immunoblotting, we loaded 15 mg of whole-cell protein extract per lane and used rabbit antibodies specific for Ras, p53, p21 (Santa Cruz Biotechnology), phosphorylated ERK1/2, total ERK1/2, phosphorylated Rb, phosphorylated Akt, total Akt (Cell Signaling Technology) and PERP (a gift from L. Attardi; Stanford University, Stanford, California, USA) and mouse antibodies specific for the Myc tag, total Rb (Santa Cruz Biotechnology), PI3K p110a (BD Transduction Laboratories), CDK4 (US Biological), hypophosphorylated Rb (BD Pharmingen) and b-actin (Sigma). We measured telomerase activation with the Trapeze ELISA Telomerase Detection Kit (Chemicon). Relative telomerase activity is calculated from the equation (A 450 -A 690 sample)/(A 450 -A 690 manufacturer's control), with data expressed relative to LacZ control, which was assigned a value of 1.0. We carried out p53 reporter assays with the internally controlled Dual-Luciferase Reporter Assay System (Promega) using luciferase reporter constructs containing a multimer of wild-type or mutant p53 binding sites 30 . Basal levels of reporter activity were consistently observed with cells in culture. We carried out TUNEL staining using the in situ death detection kit (Roche Applied Science). For RT-PCR, we extracted RNA from cells, dissected tumor specimens using Trizol reagent (Invitrogen), further purified them using the RNeasy Protect Mini Kit (Qiagen) and reverse-transcribed and amplified them using Superscript 1-step with Platinum Taq (Invitrogen). Primer sequences are available on request. We carried out immunohistochemical analysis on paraffin-embedded tissue sections, using mouse antibodies specific for pancytokeratin, HMB45 and Melan-A and rabbit antibodies specific for S100 and Ki-67 (Dako). We carried out melanin bleaching to assist visualization of immunostaining. We carried out immunofluorescence analysis on tissue cryosections and cells, using mouse antibodies against Ras, p53 (Oncogene Research Products), CDK4 (US Biological), HMB45 (Abcam) and Melan-A/MART-1 (Labvision); rat antibodies against the vascular marker CD31 (PECAM, BD Pharmingen); and rabbit antibodies for b-galactosidase (MP Biomedicals) and Ki-67 (Labvision). We counterstained sections with rabbit antibody against collagen VII (Calbiochem) and Hoechst 33342 (Molecular Probes).
